RT Journal Article
SR Electronic
T1 The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4715
OP 4718
DO 10.21873/anticanres.15285
VO 41
IS 10
A1 NATHANIEL F. WU
A1 JUN YAMAMOTO
A1 YUSUKE AOKI
A1 NORIYUKI MASAKI
A1 CARISSA SAMONTE
A1 JUSTIN WU
A1 MICHAEL BOUVET
A1 ROBERT M. HOFFMAN
YR 2021
UL http://ar.iiarjournals.org/content/41/10/4715.abstract
AB Background/Aim: Primary osteosarcoma of the breast is an exceedingly-rare malignant tumor that shares histological characteristics with osteosarcoma of the bone. Since effective therapies have not yet been established, standard therapy for osteosarcoma of the bone was examined in the present study for efficacy against primary osteosarcoma of the breast in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Materials and Methods: The PDOX mouse models were established by surgical implantation of the primary osteosarcoma of the breast specimen into the mammary gland of nude mice. Mice with tumors were randomized into four groups, each n=4: control group; cisplatinum (CDDP)-treatment group; doxorubicin (DOX)-treatment group; and CDDP/DOX-combination-treatment group. Mice were treated for twenty-one days, three weeks after implantation. Tumor size and body weight were measured during three weeks of treatment. Results: Significant tumor growth inhibition was observed, compared to the control, in the CDDP-treatment group, the DOX-treatment group, and the combination-treatment-group. Only the combination treatment regressed the tumor. Conclusion: CDDP and DOX which are standard first-line therapies for osteosarcoma, may be clinically effective against primary osteosarcoma of the breast, and in particular, their combination.